At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNTC Benitec Biopharma
Closed 11-04 16:00:00 EST
10.80
-0.12
-1.10%
盘后10.80
+0.000.00%
16:00 EST
High10.91Low10.50Vol31.94K
Open10.91D1 Closing10.92Amplitude3.75%
Mkt Cap214.00MTradable Cap195.52MTotal Shares19.82M
T/O343.59KT/O Rate0.18%Tradable Shares18.10M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
GlobeNewswire  ·  11-04 21:00
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
BRIEF-Benitec Biopharma files for mixed shelf of up to $125 mln
Reuters  ·  11-02
BRIEF-Benitec Biopharma files for mixed shelf of up to $125 mln
Benitec Biopharma (BNTC) Receives a Buy from Piper Sandler
TIPRANKS  ·  10-18
Benitec Biopharma (BNTC) Receives a Buy from Piper Sandler
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
seekingalpha  ·  10-18
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
Benitec started at outperform by Oppenheimer on gene therapy potential
seekingalpha  ·  10-17
Benitec started at outperform by Oppenheimer on gene therapy potential
Oppenheimer Initiates Coverage on Benitec Biopharma With Outperform Rating, $35 Price Target
MT Newswires Live  ·  10-16
Oppenheimer Initiates Coverage on Benitec Biopharma With Outperform Rating, $35 Price Target
Benitec Biopharma Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $35
THOMSON REUTERS  ·  10-16
Benitec Biopharma Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $35
Benitec Biopharma Initiated at Outperform by Oppenheimer
Dow Jones  ·  10-16
Benitec Biopharma Initiated at Outperform by Oppenheimer
Benitec Biopharma initiated with an Outperform at Oppenheimer
TIPRANKS  ·  10-16
Benitec Biopharma initiated with an Outperform at Oppenheimer
Benitec Biopharma participates in a conference call with Piper Sandler
TIPRANKS  ·  10-16
Benitec Biopharma participates in a conference call with Piper Sandler
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Reuters  ·  10-15
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Benitec Biopharma price target raised to $20 from $13 at Leerink
TIPRANKS  ·  10-15
Benitec Biopharma price target raised to $20 from $13 at Leerink
Benitec Biopharma price target lowered to $16 from $18 at JMP Securities
TIPRANKS  ·  10-14
Benitec Biopharma price target lowered to $16 from $18 at JMP Securities
Benitec Biopharma Announces Updated Investor Webcast Information
GlobeNewswire  ·  10-14
Benitec Biopharma Announces Updated Investor Webcast Information
Buy Rating Affirmed for Benitec Biopharma on Strong BB-301 Clinical Results and Positive Outlook
TIPRANKS  ·  10-14
Buy Rating Affirmed for Benitec Biopharma on Strong BB-301 Clinical Results and Positive Outlook
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
GlobeNewswire  ·  10-12
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
BRIEF-Benitec Biopharma Inc Co Entered Into Sales Agreement With Leerink Partners Llc
Reuters  ·  10-12
BRIEF-Benitec Biopharma Inc Co Entered Into Sales Agreement With Leerink Partners Llc
Benitec Biopharma Inc: Co Entered Into Sales Agreement With Leerink Partners Llc
THOMSON REUTERS  ·  10-12
Benitec Biopharma Inc: Co Entered Into Sales Agreement With Leerink Partners Llc
Benitec Biopharma Inc: Under the Agreement, Co to Offer up to $75 Mln of Co's Common Stock
THOMSON REUTERS  ·  10-12
Benitec Biopharma Inc: Under the Agreement, Co to Offer up to $75 Mln of Co's Common Stock
Benitec Biopharma's BB-301: Potential In OPMD But Still Too Early Stages
seekingalpha  ·  10-09
Benitec Biopharma's BB-301: Potential In OPMD But Still Too Early Stages

Introduction

Company Name.
Benitec Biopharma
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Issue price:
--